Abbott Laboratories Completes Acquisition of Exact Sciences
Abbott Laboratories (ABT) has officially announced the successful completion of its acquisition of Exact Sciences, a significant corporate development.
Results for "Abbott Laboratories"
10 stories found
Abbott Laboratories Unveils XIENCE Skypoint for Cardiovascular Treatment in India
Abbott Laboratories (ABT) has introduced XIENCE Skypoint, a new technology aimed at advancing cardiovascular treatment options in India.
Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal - Bloomberg.com
Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal Bloomberg.com
Abbott Laboratories Declares $0.63 Dividend
Abbott Laboratories has announced a dividend of $0.63 per share, providing an update on its shareholder returns.
Abbott Laboratories Earnings Preview
An article provides a preview of what to expect from Abbott Laboratories' upcoming earnings report.
Abbott Laboratories Stock Performance Analysis
An article examines if Abbott Laboratories' stock is underperforming the Nasdaq index.
Exact Sciences Shareholders Approve Acquisition by Abbott
Shareholders of Exact Sciences have given their approval for the company's acquisition by Abbott Laboratories.
Analysis: Is Abbott Laboratories (ABT) a Good Stock to Buy?
An analysis explores whether Abbott Laboratories (ABT) presents a favorable stock investment opportunity for current buyers.
Abbott Laboratories Expected to Benefit from Nutrition Segment Recovery
Abbott Laboratories (ABT) is anticipated to see positive performance driven by a recovery in its nutrition segment.
Abbott Laboratories Announces Positive Results for Amulet 360 LAA Occluder
Abbott Laboratories has reported positive clinical trial results for its Amulet 360 Left Atrial Appendage (LAA) Occluder, a device designed to prevent strokes.